Formulation of Folate Receptor-Targeted Silibinin-Loaded Inhalable Chitosan Nanoparticles by the QbD Approach for Lung Cancer Targeted Delivery
Overview
Authors
Affiliations
: Targeted delivery of chemotherapeutics by functionalized nanoparticles exhibits a wonderful prospect for cancer treatment. The main objective of this research was to develop folate receptor-targeted silibinin (SB)-loaded inhalable polymeric nanoparticles (FA-CS-SB-NPs) for the treatment of lung cancer. : The qbD approach was implemented to prepare SB-loaded nanoparticles. Folic acid was conjugated by electrostatic conjugation in an optimized batch. The therapeutic potentials of formulations were determined using a lung cancer cell-bearing rat model. : Optimized formulation exhibited a spherical surface with a mean particle size of 275 ± 1.20 nm, a PDI of 0.234 ± 0.07, a ζ-potential of 32.50 ± 0.21, an entrapment efficiency of 75.52 ± 0.87%, and a CDR of 63.25 ± 1.21% at 48 h. Aerodynamic behaviors such as the mass median aerodynamic diameter (MMAD) and geometric size distribution (GSD) were found to be 2.75 ± 1.02 and 3.15 ± 0.88 μm, respectively. After 24 h of incubation with FA-CS-SB-NPs, the IC50 value was found to be 24.5 g/mL. FA-SB-CS-NPs maintained a significantly higher deposition of SB in lung tissues. : Thus, the noninvasive nature and target specificity of FA-CS-SB-NPs pave the way for pulmonary delivery for treating lung cancer.
Fu J, Yu L, Wang Z, Chen H, Zhang S, Zhou H Medicine (Baltimore). 2025; 104(6):e41415.
PMID: 39928802 PMC: 11813027. DOI: 10.1097/MD.0000000000041415.
The Effects of Silibinin Combined With EGFR-TKIs in the Treatment of NSCLC.
Wang X Cancer Med. 2025; 14(3):e70643.
PMID: 39907159 PMC: 11795421. DOI: 10.1002/cam4.70643.
Kassaee S, Richard D, Ayoko G, Islam N Nanomedicine (Lond). 2024; 19(25):2113-2133.
PMID: 39143915 PMC: 11486133. DOI: 10.1080/17435889.2024.2387530.